Skip to main content
. 2007 Apr 18;2007(2):CD005450. doi: 10.1002/14651858.CD005450.pub2

Comparison 1. Chinese herbs versus control.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Thyroid antibody status 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Thyroglobulin antibody (TGAb) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Thyroid microsomal antibodies(TMAb) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Relapse rates 3   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
3 Thyroid function tests (dichotamous data) 7   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
3.1 Normalisation of free triiodothyronine (FT3) 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Normalisation of free thyroxine (FT4) 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Normalisation of total triiodothyronine (TT3) 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Normalisation of total thyroxine (TT4) 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Normalisation of thyroid hormones 6   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Thyroid function tests (continuous data) 8   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Thyroid‐stimulating hormone (TSH) 5   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Thyroid‐stimulating hormone (TSH)(Huangqi injection versus Jiahangling) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Free triiodothyronine (FT3) 6   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Free triiodothyronine (FT3) (Huangqi injection versus Jiakangling) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Free triiodothyronine (FT3) at 4 weeks 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 Free triiodothyronine (FT3) at 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Free thyroxine (FT4) 6   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Free thyroxine (FT4) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.9 Free thyroxine (FT4) at 4 weeks 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.10 Free thyroxine (FT4) at 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.11 Total triiodothyronine (TT3) 2   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.12 Total thyroxine (TT4) 2   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Thyroid antibody status 4   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Thyroglobulin antibodies (TGAb) 4   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Thyroglobulin antibody (TGAb) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Thyroid microsomal autoantibodies (TMAb) 3   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Thyroid microsomal antibodies(TMAb) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Symptoms of hyperthyrodism 6   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
6.1 Symptoms subsided 6   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Symptoms were markedly improved 2   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Symptoms were improved 5   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 No improvement of symptoms 5   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Weight change (improvement) 3   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
8 Adverse effects 5   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
8.1 Agranulocytosis 5   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Hepatitis 2   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Drug rash 3   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Tachycardia 3   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
9.1 Normalisation of heart rate 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Decrease in heart rate by 20 beats/min 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Decrease in heart rate by 10 beats/min 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.4 No improvement of heart rate 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.5 Normalisation of pulse rate 2   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.6 Near normalisation of pulse rate 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.7 Decrease in pulse rate 2   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.8 No improvement of pulse rate 2   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Thyroid antibody status 2   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
10.1 Reduction in thyroglobulin antibodies (>30%) and thyroid microsomal autoantibodies (>15%) 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Normalisation of thyroid‐stimulating antibodies (TSAb) 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Improvement of ophthalmopathy 1   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
12 Weight change ( weight index ) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
13 Symptoms of hyperthyroidism 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Tachycardia (heart rate) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 Diarrhoea ( frequency of stools) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]